Effect of holoBLG on Cat Allergic Patients

Status Completed

Clinical Trial Summary

The aim of the study is to investigate the antigen-unspecific effect of a 3 months supplementation with a food for special medical purposes (FSMP) in form of a lozenge containing beta-lactoglobulin (BLG), iron, retinoic acid, zinc and polyphenols (holo-BLG) in patients with allergic rhinoconjunctivitis caused by cat (hair/dander) and the associated symptoms (symptom type and severity) during exposure to cat allergen in an Allergen Exposure Chamber (AEC).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05455749
Study type	Interventional
Source	Allergy Therapeutics
Contact
Status	Completed
Phase	N/A
Start date	October 4, 2021
Completion date	March 16, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03850626` - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed	`NCT03682965` - Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study	Phase 2
Completed	`NCT04541004` - Adolescent Mite Allergy Safety Evaluation	Phase 3
Completed	`NCT02556801` - Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy	Phase 2
Completed	`NCT01918956` - PURETHAL Birch RUSH Study	Phase 4
Completed	`NCT01966224` - A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects	Phase 1
Completed	`NCT01682070` - SUBLIVAC FIX Phleum Pratense DT/DRF	Phase 2
Completed	`NCT01438463` - PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis	Phase 2
Completed	`NCT01438827` - Avanz Phleum Pratense Maintenance Dose	Phase 2/Phase 3
Completed	`NCT02437786` - Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®	Phase 4
Completed	`NCT00985296` - Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)	N/A
Completed	`NCT01740284` - A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine	Phase 3
Completed	`NCT04912076` - S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen	Phase 1
Completed	`NCT03365648` - Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics	N/A
Completed	`NCT01707069` - A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid	Phase 1
Completed	`NCT01567306` - Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense	Phase 2
Completed	`NCT01466465` - Vitamin D and Grass Pollen Specific Immunotherapy	Phase 2
Completed	`NCT01490411` - Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis	Phase 2
Completed	`NCT00777374` - Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration	Phase 2
Active, not recruiting	`NCT04502966` - Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction	Phase 2